In a paper published this month in Frontiers in Psychiatry, scientists at NeuroPointDX, a division of Stemina Biomarker Discovery, Inc., in collaboration with researchers at the UC Davis MIND Institute and the Cleveland Clinic as well as academic and clinical institutions across the country, report new findings from the Children’s Autism Metabolome Project or CAMP.
CAMP is the largest study the metabolism of children, ages 18 to 48 months, with autism spectrum disorder (ASD). The paper reports unique metabolic subtypes in 72% of the children with autism in the study. The addition of a third validated test panel for these metabolic subtypes results in an overall accuracy of the NPDX Test Panels of 81%. Each subtype provides insight into the unique metabolic dysregulation of the child and helps inform more precise treatment based upon the biology of the individual.
“This is the frontier of precision medicine for our children with ASD” – says CEO, Elizabeth Donley whose 27 year old son is on the spectrum. “Rather than reading about modified diets, dietary supplements, probiotics, drugs and other treatments that work for some children and trying them without any insight into what might work for the individual child, we can inform more precise intervention earlier when neuro-development is rapidly occurring and the brain is very plastic“.
Read the publication: Frontiers in Psychiatry
